nVerses Capital LLC Grows Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

nVerses Capital LLC lifted its position in REGENXBIO Inc. (NASDAQ:RGNX) by 183.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,400 shares of the biotechnology company’s stock after purchasing an additional 2,200 shares during the quarter. nVerses Capital LLC’s holdings in REGENXBIO were worth $36,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in REGENXBIO by 80.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 170,218 shares of the biotechnology company’s stock worth $3,586,000 after buying an additional 75,800 shares in the last quarter. Integral Health Asset Management LLC boosted its stake in shares of REGENXBIO by 25.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after purchasing an additional 190,000 shares in the last quarter. Quest Partners LLC grew its holdings in shares of REGENXBIO by 11,731.0% during the 2nd quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 41,645 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of REGENXBIO by 8.3% during the 1st quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 874 shares during the last quarter. Finally, Squarepoint Ops LLC raised its position in REGENXBIO by 630.9% in the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock worth $1,711,000 after purchasing an additional 126,249 shares during the period. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Trading Down 7.5 %

NASDAQ:RGNX opened at $9.59 on Wednesday. The company has a 50-day moving average price of $11.26 and a 200-day moving average price of $13.17. The stock has a market cap of $473.94 million, a price-to-earnings ratio of -1.82 and a beta of 1.21. REGENXBIO Inc. has a 12 month low of $9.11 and a 12 month high of $28.80.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The business had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $22.97 million. During the same period in the previous year, the firm posted ($1.66) EPS. The business’s revenue was up 11.6% on a year-over-year basis. Equities analysts forecast that REGENXBIO Inc. will post -4.66 EPS for the current fiscal year.

Insider Activity at REGENXBIO

In other REGENXBIO news, CEO Curran Simpson sold 9,648 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $15.04, for a total value of $145,105.92. Following the completion of the transaction, the chief executive officer now owns 170,137 shares in the company, valued at approximately $2,558,860.48. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total value of $115,600.00. Following the sale, the director now directly owns 11,286 shares of the company’s stock, valued at $130,466.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Curran Simpson sold 9,648 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $15.04, for a total value of $145,105.92. Following the transaction, the chief executive officer now directly owns 170,137 shares of the company’s stock, valued at approximately $2,558,860.48. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,848 shares of company stock worth $665,197 over the last ninety days. 13.13% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RGNX. HC Wainwright restated a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. Chardan Capital restated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Tuesday. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Raymond James reissued an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Finally, Barclays decreased their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.45.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.